Because of the above noted changes to the collections, FDA has resubmitted the matter to OMB for review and approval and prior to the effective date of the rule, FDA will publish a notice in the Federal Register of OMB's action on the provisions.
FDA had to resubmit the matter to OMB because it was previously rejected.